Stellate ganglion block for treating hot flashes: A viable treatment option or sham procedure?

Maturitas

Volumn 76, Issue 3, 2013, Pages 221-224

  Guttuso, Thomas ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Flush; Hot flash; Menopause; Non hormonal; Sympathetic chain; Vasomotor symptoms

Indexed keywords

BUPIVACAINE; CONTRAST MEDIUM; LEVOBUPIVACAINE;

CLINICAL TRIAL (TOPIC); CONTRAST ENHANCEMENT; FLUOROSCOPY; HOT FLUSH; HUMAN; OPEN STUDY; PAIN; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SHAM PROCEDURE; STELLATE GANGLION BLOCK;

FLUSH; HOT FLASH; MENOPAUSE; NON-HORMONAL; SYMPATHETIC CHAIN; VASOMOTOR SYMPTOMS;

AUTONOMIC NERVE BLOCK; FEMALE; HOT FLASHES; HUMANS; MENOPAUSE; PLACEBO EFFECT; STELLATE GANGLION;

EID: 84887494742     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2013.08.001     Document Type: Review

References (25)

1. E. Lipov, S. Lipov, and J.T. Stark Stellate ganglion blockade provides relief from menopausal hot flashes: a case report series J Womens Health (Larchmt) 14 2005 737 741
2. M. Gofeld, A. Bhatia, S. Abbas, S. Ganapathy, and M. Johnson Development and validation of a new technique for ultrasound-guided stellate ganglion block Reg Anesth Pain Med 34 2009 475 479
3. E.G. Lipov, J.R. Joshi, S. Sanders, K. Wilcox, S. Lipov, and H. Xie Effects of stellate-ganglion block on hot flushes and night awakenings in survivors of breast cancer: a pilot study Lancet Oncol 9 2008 523 532
4. H. Wulf, and C. Maier Complications and side effects of stellate ganglion blockade: results of a questionnaire survey Anaesthesist 41 1992 146 151
5. C.L. Loprinzi, D.L. Barton, and P.E. Carns Stellate-ganglion block: a new treatment for hot flushes Lancet Oncol 9 2008 506 507
6. R.R. Freedman, M.D. Benton, R.J. Genik 2nd, and F.X. Graydon Cortical activation during menopausal hot flashes Fertil Steril 85 2006 674 678
7. U.S. Department of Health and Human Services FDA. Guidance for Industry: estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms- recommendations for clinical evaluation, 1/2003. Available at: www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071643.pdf, accessed 13.06.13.
8. T. Guttuso Jr. Effective and clinically meaningful non-hormonal hot flash therapies Maturitas 72 2012 6 12
9. D.R. Pachman, D. Barton, P.E. Carns, P.J. Novotny, S. Wolf, and B. Linquist Pilot evaluation of a stellate ganglion block for the treatment of hot flashes Support Care Cancer 19 2011 941 947
10. P. van Gastel, J.W. Kallewaard, M. van der Zanden, and H. de Boer Stellate-ganglion block as a treatment for severe postmenopausal flushing Climacteric 16 2013 41 47
11. K. Haest, A. Kumar, B. Van Calster, K. Leunen, A. Smeets, and F. Amant Stellate ganglion block for the management of hot flashes and sleep disturbances in breast cancer survivors: an uncontrolled experimental study with 24 weeks of follow-up Ann Oncol 23 2012 1449 1454
12. M.S. Hendy, B. Cockrill, and P.S. Burge The effects of naloxone infusion and stellate ganglion blockade on hot flushes in the human male Maturitas 7 1985 169 174
13. H. Wilhelm Disorders of the pupil handbook Clin Neurol 102 2011 427 466
14. T. Guttuso, and M. Evans Minimum trial duration to reasonably assess long-term efficacy of nonhormonal hot flash therapies J Womens Health (Larchmt) 19 2010 699 702
15. T. Forouzanfar, M. van Kleef, and W.E. Weber Radiofrequency lesions of the stellate ganglion in chronic pain syndromes: retrospective analysis of clinical efficacy in 86 patients Clin J Pain 16 2000 164 168
16. D.F. Archer, L. Seidman, G.D. Constantine, J.H. Pickar, and S. Olivier A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause Am J Obstet Gynecol 200 172 2009 e1 e10
17. P. Bouchard, N. Panay, T.J. de Villiers, P. Vincendon, W. Bao, and R.J. Cheng Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms Climacteric 15 2012 12 20
18. S.Y. Reddy, H. Warner, T. Guttuso Jr., S. Messing, W. Digrazio, and L. Thornburg Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial Obstet Gynecol 108 2006 41 48
19. M.G. Bergmans, J.M. Merkus, R.S. Corbey, L.A. Schellekens, and J.M. Ubachs Effect of bellergal retard on climacteric complaints: a double-blind, placebo-controlled study Maturitas 9 1987 227 234
20. P.I. Clark, and P.E. Leaverton Scientific and ethical issues in the use of placebo controls in clinical trials Annu Rev Public Health 15 1994 19 38
21. D.C. Martin, M.L. Willis, L.A. Mullinax, N.L. Clarke, J.A. Homburger, and I.H. Berger Pulsed radiofrequency application in the treatment of chronic pain Pain Pract 7 2007 31 35
22. B. Ettinger Vasomotor symptom relief versus unwanted effects: role of estrogen dosage Am J Med 118 Suppl 12B 2005 74 78
23. J.E. Rossouw, G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, and M.L. Stefanick Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial JAMA 288 2002 321 333
24. M. Healy FDA approves an antidepressant for hot flashes 2013 Available at: http://articles.latimes.com/2013/jun/28/science/la-sci-fda-antidepressant- hot-flashes-20130628, accessed: 6.08.13
25. Administration USFaD FDA approves the first non-hormonal treatment for hot flashes associated with menopause 2013 Available at: http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm359030.htm, accessed 6.08.13